4.8 Review

HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist

期刊

JOURNAL OF HEPATOLOGY
卷 77, 期 2, 页码 503-515

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2022.03.007

关键词

organ transplantation; HBV; HIV; non-optimal donors; antiviral therapy; antiviral prophylaxis

向作者/读者索取更多资源

Organ transplantation is a life-saving treatment for patients with end-stage organ disease, but it is limited by a shortage of available organs. In recent years, there have been explorations and attempts to transplant organs from HBV and HIV positive donors in some countries. However, post-transplant antiviral therapies are necessary to prevent virus reactivation, and intentional virus transmission has practical, ethical, and clinical implications.
Organ transplantation is a life-saving treatment for patients with end-stage organ disease, a severe condition associated with a high risk of waitlist mortality. It is primarily limited by a shortage of available organs. Maximising available donors can increase access to transplantation. Transplantation from donors positive for HBV and HIV has increased in many countries. However, antiviral therapies need to be readily available for recipients after transplantation to prevent possible reactivation of the virus following the administration of immunosuppressive therapies. Furthermore, the intentional transmission of a virus has practical, ethical, and clinical implications. In this review, we summarise the current research, focusing on grafts from donors positive for the HBV surface antigen, antibodies against the HBV core antigen, and HIV, to help hepatologists and physicians interested in transplantation to select the best antiviral and/or prophylactic regimens for after transplantation. (C) 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据